Qualigen Therapeutics (QLGN) Files for 14M Share and Warrant Offering

Qualigen Therapeutics (NASDAQ: QLGN) has filed the following:

We are offering on a “reasonable best efforts” basis up to 14,000,000 shares of common stock, par value $0.001 per share (the “common stock”).

We are also offering pre-funded warrants (the “pre-funded warrants”) to purchase up to an aggregate of shares of common stock to those purchasers whose purchase of shares of common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, in lieu of shares of common stock that would result in beneficial ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant is exercisable for one share of our common stock, has an exercise price of $0.001 per share and an indefinite term. For each pre-funded warrant that we sell, the number of shares of common stock we are offering will be reduced on a one-for-one basis.

You May Also Be Interested In

• Blackstone invests in Korean actuator maker Futronic
• Brazil's ANAC releases proposed noise rules for Eve Air Mobility eVTOL
• Boeing projects $4.9T aviation services market through 2045